Behavioral Interventions can help smokers with diabetes quit with a greater likelihood of success. However, structured programs are needed

The results were included in the review "Behavioural therapy for people with diabetes who smoke: a scoping review," published in the Journal of Primary Care and Community Health: it is now clear that persons living with diabetes are not the subject of targeted treatments and that there is ample room for progress. It seems that more structured and intensive therapies could benefit these persons in bidding farewell to cigarette smoking, while little is still known about the possible benefits of combining  behavioral therapies and nicotine replacement pharmacological therapies.

Continue ReadingBehavioral Interventions can help smokers with diabetes quit with a greater likelihood of success. However, structured programs are needed

At GFN 2023, SAB Diasmoke second meeting

GFN 2023 will start tomorrow at Varsavia. The 10th edition of the Global Forum on Nicotine, from 21 to 24 June, will host more events dedicated to harm reduction research. During this edition will be also the second meeting of SAB Diasmoke. Diabetologists and experts on THR signed the guidelines on the treatment of smokers with diabetes.

Continue ReadingAt GFN 2023, SAB Diasmoke second meeting

Diabetes and smoking: international meeting on the development of new guidelines in Catania

Ten of the world’s leading experts in diabetes addressed the issue of smoking harm in this vulnerable population in its clinical, medical, behavioral and sociological implications, in order to provide independent consultation and oversight to the development of smoking cessation / harm reduction guidelines for smokers with type 2 diabetes mellitus.

Continue ReadingDiabetes and smoking: international meeting on the development of new guidelines in Catania

First study in the world to evaluate efficacy and safety of the antismoking drug varenicline for smokers with Diabetes

A recent randomized controlled trial of varenicline (Chantix) combined with psychological support has significantly increased the chance of quitting smoking for 300 smokers with type 2 diabetes mellitus

Continue ReadingFirst study in the world to evaluate efficacy and safety of the antismoking drug varenicline for smokers with Diabetes

The first review to assess the metabolic impact of stopping smoking in patients with diabetes mellitus revealed serious gaps in the literature

Quitting smoking can reduce cardiovascular and kidney failure risks. However, it can lead to side effects such as weight gain. A scoping review conducted by a pool of European researchers revealed a lack of data on the metabolic effects of smoking and smoking cessation in diabetes. Healthcare professionals should not assume that cessation of smoking will improve metabolic parameters in patients with diabetes.

Continue ReadingThe first review to assess the metabolic impact of stopping smoking in patients with diabetes mellitus revealed serious gaps in the literature